| dc.creator | Melgaço, Juliana Gil | |
| dc.creator | Azamor, Tamiris | |
| dc.creator | Ano Bom, Ana Paula Dinis | |
| dc.date | 2022-02-25T14:16:20Z | |
| dc.date | 2022-02-25T14:16:20Z | |
| dc.date | 2020 | |
| dc.date.accessioned | 2023-09-26T20:21:08Z | |
| dc.date.available | 2023-09-26T20:21:08Z | |
| dc.identifier | MELGAÇO, Juliana Gil; AZAMOR, TTamiris; ANO BOM, Ana Paula Dinis. Protective immunity after COVID-19 has been questioned: what can we do without SARS-CoV-2-IgG detection? Cellular Immunology, n. 353, p. 1-3, Jul. 2020. | |
| dc.identifier | 0008-8749 | |
| dc.identifier | https://www.arca.fiocruz.br/handle/icict/51490 | |
| dc.identifier | 10.1016/j.cellimm.2020.104114 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/8854911 | |
| dc.description | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. | |
| dc.description | O coronavírus 2 da síndrome respiratória aguda grave (SARS-CoV-2) induz uma síndrome respiratória aguda grave chamada COVID-19. As manifestações clínicas do COVID-19 incluem diarreia, pneumonia, linfopenia, linfócitos esgotados e produção de citocinas pró-inflamatórias. A imunologia faz parte do processo de
evolução clínica, mas existem algumas questões em torno da proteção baseada na imunidade: (1) por que algumas pessoas infectadas apresentam apenas sintomas leves da doença ou são assintomáticas; (2) por que as respostas tardias e fracas de anticorpos estão associadas a desfechos graves; e (3) por que a positividade em testes moleculares não representa
anticorpo protetor IgG. Talvez as respostas das células T possam ser a chave para resolver essas questões. As células T de memória específicas para SARS-CoV-2 persistem no sangue periférico e podem ser capazes de fornecer informações eficazes sobre imunidade protetora. Os estudos com células T podem ser úteis na elucidação dos caminhos para o desenvolvimento de vacinas,
terapias e diagnósticos para COVID-19 e para preencher essas lacunas de conhecimento em imunologia. | |
| dc.description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a severe acute respiratory syndrome that is called COVID-19. Clinical manifestations of COVID-19 include diarrhea, pneumonia, lymphopenia, exhausted lymphocytes, and pro-inflammatory cytokine production. Immunology is part of the process of
clinical evolution, but there are some questions around immunity-based protection: (1) why some infected people have only mild symptoms of the disease or are asymptomatic; (2) why delayed and weak antibody responses are associated with severe outcomes; and (3) why positivity in molecular tests does not represent
protective antibody IgG. Perhaps T cell responses may be the key to solving those questions. SARS-CoV-2-specific memory T cells persist in peripheral blood and may be capable of providing effective information about protective immunity. The T cells studies can be helpful in elucidating the pathways for development of vaccines,
therapies, and diagnostics for COVID-19 and for filling these immunology knowledge gaps. | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.rights | open access | |
| dc.subject | Coronavírus | |
| dc.subject | COVID-19 | |
| dc.subject | SARS-CoV-2-IgG | |
| dc.subject | Coronavirus | |
| dc.subject | COVID-19 | |
| dc.subject | SARS-CoV-2-IgG | |
| dc.subject | Coronavírus | |
| dc.title | Protective immunity after COVID-19 has been questioned: What can we do without SARS-CoV-2-IgG detection? | |
| dc.type | Article | |
